



Biology Driven Treatment Strategy for Breast Cancer

Guest Editor:

Dr. Akihiko Shimomura

Department of Breast and
Medical Oncology, National
Center for Global Health and
Medicine, Tokyo 162-8655, Japan

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editor

Dear Colleagues,

Currently, breast cancer is classified by hormone receptor, HER2, and Ki67 status. These biomarkers are predictors of response to treatment, and treatment options such as endocrine therapy and anti-HER2 therapy are selected according to the biomarkers' expression status. However, when patients become resistant to these targeted therapies or no biomarkers are expressed, chemotherapy without specific predictors of efficacy is currently the treatment of choice. Many biomarkers such as TROP-2, HER3, PD-L1, and germline BRCA1/2 mutations have been developed, and targeted therapies for each biomarker have been applied in the clinical setting. Optimal breast cancer treatment using these biomarkers will be discussed.

Dr. Akihiko Shimomura
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)